Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Lesokhin Discusses Exciting Advances in Multiple Myeloma
July 14th 2018Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.
Regorafenib Dose-Escalation Superior to Standard Dosing in mCRC
June 22nd 2018Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.
Dr. Finn Recaps Second-Line Advancements in HCC
June 22nd 2018Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.
Pembrolizumab Fails to Show Survival Benefit in PD-L1 ≥1 Gastric/GEJ Cancers
June 21st 2018Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.
Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers
June 21st 2018George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.
Adding SIRT Does Not Provide Survival Benefit in Advanced HCC, Except in Select Patients
Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.
Dr. Finn Discusses the Pooled Analysis of REACH and REACH-2 in HCC
June 20th 2018Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the pooled analysis of the REACH and REACH-2 studies in patients with hepatocellular carcinoma.
Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma
June 17th 2018The addition of elotuzumab to pomalidomide and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.
Quizartinib Extends Survival in FLT3-ITD+ Relapsed/Refractory AML
June 17th 2018Quizartinib reduced the risk of death by 24% compared with salvage chemotherapy in patients with FLT3-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.
CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL
June 16th 2018A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.
Dr. Cortes on the Results of Quizartinib in Relapsed/Refractory AML
June 16th 2018Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the results of quizartinib in patients with relapsed/refractory acute myeloid leukemia.
Dr. Davids Discusses Duvelisib Plus FCR in Young Patients With CLL
June 16th 2018Matthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.
